Benova Mouth Rinse Study Shows Significant Reduction in Inflammatory Marker TNF-Alpha
A recent study presented at the 2025 Diabetic Limb Salvage Conference reveals the Benova Mouth Rinse System's ability to reduce TNF-alpha, a key inflammatory marker, by 17% within two minutes, offering potential relief for millions suffering from oral inflammatory conditions.
Results from a study on the Benova Mouth Rinse System, presented at the 2025 Diabetic Limb Salvage Conference, highlight its potential to significantly reduce inflammation. The research, conducted at the University of Alabama Capstone College of Nursing, demonstrated a 17% reduction in tumor necrosis factor-alpha (TNFα), a critical inflammatory marker, within just two minutes of application. This finding is particularly relevant for the millions worldwide suffering from oral mucositis, canker sores, and other inflammatory oral conditions, where TNFα plays a central role in driving inflammation and cell damage.
The study utilized an in vitro model of inflamed oral mucosa to simulate conditions commonly found in patients undergoing cancer therapy or those with chronic inflammatory wounds. The Benova Mouth Rinse System achieved its anti-inflammatory effects without the use of lidocaine, steroids, or prescription medications, marking a significant advancement in non-invasive treatment options. Dr. Daniel J. Gibson, the study's presenter, emphasized the potential of Benova to alleviate pain and support healing through targeted cytokine reduction.
Bill Kling, co-founder of Benova, noted the alignment between the study's results and anecdotal evidence from users who report rapid pain relief and healing of oral ulcers. The presentation of these findings at the Diabetic Limb Salvage Conference underscores the importance of innovative solutions in wound care and tissue regeneration, particularly for diabetic patients prone to complex foot and limb wounds. The full scientific rationale and poster findings are available here.